AbbVie Will Pay Up To $840M For Ablynx Licensing Deal
AbbVie Inc. has inked a licensing agreement with Belgian biopharmaceutical company Ablynx NV that could see AbbVie paying up to $840 million to develop and commercialize an experimental drug for lupus...To view the full article, register now.
Already a subscriber? Click here to view full article